Clinical Trials Logo

Candidiasis, Oral clinical trials

View clinical trials related to Candidiasis, Oral.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05761197 Not yet recruiting - Clinical trials for Early Childhood Caries

Oropharyngeal Candidiasis (OPC) and S-ECC

Oral-Thrush
Start date: July 1, 2024
Phase:
Study type: Observational

The overall objective of this study is to investigate the association of early Candida infection (known as oral thrush or oropharyngeal candidiasis, OPC) in children during the first year of life with the onset and severity of severe early childhood caries (S-ECC).

NCT ID: NCT05289375 Not yet recruiting - Clinical trials for Microbial Colonization

Efficacy of the Vacucis Candida® Autovaccine

Start date: April 30, 2024
Phase: N/A
Study type: Interventional

Introduction: Oral candidiasis is an infectious disease caused by the growth of Candida colonies and their penetration into oral tissues when physical barriers and host defenses are weakened. It constitutes one of the most common pathologies within the field covered by Dentistry. Candida infections are found in at least 80% of AIDS patients and in a third of HIV infection cases. Systemic diseases such as diabetes and a wide pharmacological arsenal to which the general population is subjected, are other causes of the increase in the prevalence of this disease. In addition, the high prevalence of oral sequelae (hyposialia) in the population over 65 years of age, due to the specific characteristics of this age group, such as multiple pathologies and drug use, explains the presence of this disease in this segment. of the population One of the great difficulties for the study of this disease is the diversity of predisposing factors, which do nothing but throw greater confusion into the results of the different works. Objective: To evaluate the reduction/suppression of signs and symptoms of oral candidiasis in patients treated with head and neck RT, users of Vacucis or Placebo. Material and method: Patients will receive information regarding the trial and, if they meet the inclusion criteria and agree to participate in it, they will sign the informed consent. All patients will be informed following the usual care practice of the characteristics of their candidiasis infection as well as the possibilities and alternatives of treatment and their respective efficacy. A descriptive analysis of the sample in terms of prevalence will be carried out. Categorical variables will be described as frequency and percentage and continuous variables as mean and standard deviation or median and interquartile range depending on their adjustment to normality, which will be calculated with the Kolmogorov-Smirnov test. To study the effect of the vaccine on the evolution of candidiasis, the Chi-square test, Student's t test or the non-parametric Mann-Whitney test will be used. The association of prevalence with CFU in both groups will be analyzed using the ANOVA test. Those values of p < 0.05 will be considered significant.

NCT ID: NCT03250923 Not yet recruiting - Candidiasis, Oral Clinical Trials

CelAgaceā„¢ OraRinse Solution for Treatment of Candidiasis

Start date: September 2024
Phase: Phase 1/Phase 2
Study type: Interventional

CelAgaceā„¢ OraRinse (silver citrate complex and acemannan) Solution is planned to be evaluated for safety and effectiveness as a potential treatment for candidiasis, a yeast infection, commonly known as thrush, which is associated with mouth sores.